Last reviewed · How we verify
NCT04406688
Prediction of Acute Kidney Injury in Patients With COVID-19
trial in Acute Kidney Injury in 300 participants. Completed in 31 March 2022.
30 December 2021
Quick facts
| Lead sponsor | University Hospital Muenster |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 22 June 2020 |
| Primary completion | 30 December 2021 |
| Estimated completion | 31 March 2022 |
| Sites | 13 locations across Italy, United Kingdom, Germany, Portugal, Spain |
Conditions studied
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
- COVID-19 — all drugs for COVID-19 →
- ARDS — all drugs for ARDS →
Sponsor
University Hospital Muenster
Who can join
18 and older, any sex, with Acute Kidney Injury or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The two biomarkers determined in urine, "Tissue Inhibitor of Metalloproteinases 2 (TIMP-2)" and "Insulin-like Growth Factor-Binding Protein 7 (IGFBP7)", can indicate the occurrence of Acute kidney injury (AKI) in cardiac surgery and critically ill patients at an early stage. However, no data are available whether these parameters can also predict the occurrence of AKI in the context of COVID-19 infection. An early prediction of AKI can be helpful for the optimisation of therapeutic management to improve patient outcome and for the triage of patients. The aim of this observational study is to evaluate whether the biomarker \[TIMP- 2\]\*\[IGFBP7\] can predict the occurrence of AKI in critically ill patients suffering from SARS-CoV2 associated acute respiratory distress syndrome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Role of Cell Cycle Arrest Biomarkers for Predicting Acute Kidney Injury in Critically Ill COVID-19 Patients: A Multicenter, Observational Study.
Weiss R, von Groote T, Ostermann M, Lumlertgul N, et al · · 2023 · cited 10× · PMID 36975308 · DOI 10.1097/ccm.0000000000005853
Verify or expand the search:
- PubMed search for NCT04406688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Kidney Injury
Currently open trials in the same condition.
- NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
- NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
- NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
- NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
- NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting
Other University Hospital Muenster trials
Trials by the same sponsor.
- NCT07414498 — MICRO-SURG: Subgingival Microbiome in Peri-Implantitis, Regenerative, and Resective Periodontal Surgery · NA · not yet recruiting
- NCT06999174 — Multiparametric MRI for Characterization of Hepatocellular Carcinoma · recruiting
- NCT06980740 — Video-Tumorboard PLUS · recruiting
- NCT06648733 — Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care · NA · recruiting
- NCT06464302 — Investigation of the Effect of Age and Injury Severity on Short-term Intra-hospital Outcomes After Surgical Stabilized R · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04406688 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Muenster
- Last refreshed: 7 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04406688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing